Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double-Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study

• Published in: Gut and liver Vol. 15; no. 6; pp. 841 - 850
• Main Authors: Kim, Gwang Ha, Lee, Hang Lak, Joo, Moon Kyung, Park, Hong Jun, Jung, Sung Woo, Lee, Ok-Jae, Kim, Hyungkil, Chun, Hoon Jai, Lee, Soo Teik, Kim, Ji Won, Jeon, Han Ho, Chung, Il-Kwun, Kim, Hyun-Soo, Lee, Dong Ho, Kim, Kyoung-Oh, Lim, Yun Jeong, Park, Seun-Ja, Cho, Soo-Jeong, Kim, Byung-Wook, Ko, Kwang Hyun, Jeon, Seong Woo, Kim, Jae Gyu, Sung, In-Kyung, Kim, Tae Nyeun, Sung, Jae Kyu, Park, Jong-Jae
• Format: Journal Article
• Language: English
• Published: Korea (South) Editorial Office of Gut and Liver 15.11.2021; Gastroenterology Council for Gut and Liver; 거트앤리버 소화기연관학회협의회
• Subjects: adverse drug reaction; gastritis; intention-to-treat analysis; Original; phase iii clinical trial; rebamipide; 내과학; Rebamipide; Intention-to-treat analysis; Adverse drug reaction; Phase III clinical trial; Gastritis

: The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers. We compared the efficacy of Mucosta (rebamipide 100 mg) and its new formulation, AD-203 (rebamipide 150 mg), in treating erosive gastritis. This double-blind, active control, noninferiority, multicenter, phase 3 clini...